About Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG)
TetraLogic Pharmaceuticals Corporation is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics in oncology, infectious diseases and autoimmune diseases. The Company's segment is the identification and development of novel small molecule therapies in oncology and infectious diseases. The Company has approximately two clinical-stage product candidates in development, such as birinapant and SHAPE. SHAPE is the Company's histone deacetylase (HDAC) inhibitor that it is developing for topical use for the treatment of early-stage cutaneous T-cell lymphoma (CTCL). The Company is also exploring studying SHAPE in alopecia areata, an autoimmune skin disease. SHAPE has been granted the United States orphan drug designation for CTCL. Birinapant is a small molecule therapeutic that mimics Second Mitochondrial Activator of Caspases (SMAC)-mimetic, which leads to apoptosis or cell-death in damaged cells.
Industry, Sector and Symbol:
- Market Cap: $1.03 million
- Outstanding Shares: 24,769,000
- 50 Day Moving Avg: $0.03
- 200 Day Moving Avg: $0.03
- 52 Week Range: $0.02 - $0.17
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -0.04
- P/E Growth: 0.00000
- Annual Revenue: N/A
- Price / Sales: N/A
- Book Value: ($1.25) per share
- Price / Book: -0.03
- EBITDA: ($21,140,000.00)
- Return on Assets: -73.81%
- Debt-to-Equity Ratio: -1.00%
- Current Ratio: 0.48%
- Quick Ratio: 0.48%
- Average Volume: 70,642 shs.
- Beta: 3
- Short Ratio: 4.39
Frequently Asked Questions for Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG)
What is Tetralogic Pharmaceuticals Corp's stock symbol?
Tetralogic Pharmaceuticals Corp trades on the NASDAQ under the ticker symbol "TLOG."
How were Tetralogic Pharmaceuticals Corp's earnings last quarter?
Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG) released its quarterly earnings data on Thursday, February, 26th. The company reported ($0.53) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.39) by $0.14. View Tetralogic Pharmaceuticals Corp's Earnings History.
When will Tetralogic Pharmaceuticals Corp make its next earnings announcement?
Who are some of Tetralogic Pharmaceuticals Corp's key competitors?
Some companies that are related to Tetralogic Pharmaceuticals Corp include Affymax (AFFY), CSL Limited (CSL), Cubist Pharmaceuticals (CBST), Dendreon (DNDN), DNIB Unwind (BIND), Durata Therapeutics (DRTX), Epirus Biopharmaceuticals (EPRS), Humanigen (KBIO), Idenix Pharmaceuticals (IDIX), InterMune (ITMN), LipoScience (LPDX), Mast Therapeutics (MSTX), Oncolytics Biotech (ONCY), Onyx Pharmaceuticals (ONXX), Sirtex Medical Limited (SRX) and Trius Therapeutics (TSRX).
Who are Tetralogic Pharmaceuticals Corp's key executives?
Tetralogic Pharmaceuticals Corp's management team includes the folowing people:
- Andrew L. Pecora M.D., Independent Chairman of the Board
How do I buy Tetralogic Pharmaceuticals Corp stock?
Shares of Tetralogic Pharmaceuticals Corp can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Tetralogic Pharmaceuticals Corp's stock price today?
MarketBeat Community Rating for Tetralogic Pharmaceuticals Corp (NASDAQ TLOG)MarketBeat's community ratings are surveys of what our community members think about Tetralogic Pharmaceuticals Corp and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Tetralogic Pharmaceuticals Corp stock can currently be purchased for approximately $0.04.
Consensus Ratings for Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|Consensus Price Target History for Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG)
Analysts' Ratings History for Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG)
(Data available from 10/22/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|1/7/2016||Roth Capital||Lower Price Target||Buy||$5.00 -> $1.00||N/A|
Earnings History for Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG)Earnings History by Quarter for Tetralogic Pharmaceuticals Corp (NASDAQ TLOG)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/2/2017|| || || || || || || || |
Earnings Estimates for Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG)
Current Year EPS Consensus Estimate: $-1.77000 EPS
Next Year EPS Consensus Estimate: $-0.99000 EPS
Dividend History for Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG)
Insider Ownership Percentage: 24.00%Insider Trades by Quarter for Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG)
Institutional Ownership Percentage: 2.69%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|2/9/2016||Lifesciences Ii L.P. Clarus||Major Shareholder||Sell||333,630||$0.17||$56,717.10|| |
|2/5/2016||Lifesciences Ii L.P. Clarus||Major Shareholder||Sell||1,415,490||$0.18||$254,788.20|| |
|2/2/2016||Lifesciences Ii L.P. Clarus||Major Shareholder||Sell||369,132||$0.19||$70,135.08|| |
|1/28/2016||Lifesciences Ii L.P. Clarus||Major Shareholder||Sell||311,930||$0.28||$87,340.40|| |
|7/10/2015||Andrew L Pecora||Director||Buy||50,000||$2.68||$134,000.00|| |
|7/9/2015||Andrew L Pecora||Director||Buy||50,000||$2.40||$120,000.00|| |
|7/2/2015||Paul J Schmitt||Director||Buy||10,000||$2.34||$23,400.00|| |
|3/27/2015||Pete A Meyers||CFO||Buy||5,000||$4.35||$21,750.00|| |
|3/26/2015||J Kevin Buchi||CEO||Buy||5,000||$4.23||$21,150.00|| |
|1/7/2015||J Kevin Buchi||CEO||Buy||5,000||$5.04||$25,200.00|| |
|12/10/2014||Colin Glenn Begley||SVP||Buy||5,900||$6.16||$36,344.00|| |
|12/9/2014||J Kevin Buchi||CEO||Buy||5,000||$6.01||$30,050.00|| |
|12/4/2014||Pete A Meyers||CFO||Buy||1,034||$4.94||$5,107.96|| |
|12/2/2014||J Kevin Buchi||CEO||Buy||10,000||$4.99||$49,900.00|| |
|11/26/2014||Colin Glenn Begley||SVP||Buy||3,100||$4.86||$15,066.00|| |
|11/26/2014||Lesley Russell||COO||Buy||20,000||$4.90||$98,000.00|| |
|11/25/2014||Colin Glenn Begley||SVP||Buy||2,000||$4.85||$9,700.00|| |
|11/18/2014||J Kevin Buchi||CEO||Buy||10,000||$4.82||$48,200.00|| |
|11/17/2014||Andrew L Pecora||Director||Buy||20,000||$4.53||$90,600.00|| |
|11/12/2014||Peter A Meyers||CFO||Buy||5,000||$3.98||$19,900.00|| |
|11/11/2014||J Kevin Buchi||CEO||Buy||10,000||$3.93||$39,300.00|| |
|11/10/2014||Paul J Schmitt||Director||Buy||20,000||$4.10||$82,000.00|| |
|12/17/2013||J Kevin Buchi||CEO||Buy||285,714||$7.00||$1,999,998.00|| |
|12/17/2013||James N Woody||Director||Buy||261,427||$7.00||$1,829,989.00|| |
|12/17/2013||Peter A Meyers||CFO||Buy||142,857||$7.00||$999,999.00|| |
|12/17/2013||Ventures Vii Lp Healthcare||Major Shareholder||Buy||713,463||$7.00||$4,994,241.00|| |
Headline Trends for Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG)
Latest Headlines for Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG)
Loading headlines, please wait.
Tetralogic Pharmaceuticals Corp (TLOG) Chart for Sunday, October, 22, 2017